Compare TCI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | BWAY |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.6M | 578.5M |
| IPO Year | 1994 | 2011 |
| Metric | TCI | BWAY |
|---|---|---|
| Price | $38.97 | $13.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 55.5K | ★ 107.3K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,060,000.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $31.48 | $11.77 |
| 52 Week High | $59.65 | $26.63 |
| Indicator | TCI | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 40.31 |
| Support Level | $39.05 | $11.90 |
| Resistance Level | $41.67 | $14.83 |
| Average True Range (ATR) | 1.78 | 0.47 |
| MACD | 0.34 | -0.04 |
| Stochastic Oscillator | 71.62 | 3.85 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.